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ABSTRACT
To understand the factors associated with non-
adherence to oral antiplatelet (OAP) therapy in acute
coronary syndromes (ACS), and where interventions
have modified these factors. Linked systematic reviews
were undertaken in accordance with the Preferred
Reporting Items for Systematic reviews and Meta-
analysis guidelines, using CINAHL Plus, MEDLINE,
PsycINFO and PubMed databases. The searches were
limited to studies available in English and published
from 2000 onwards; last run in June 2015. Review 1:
factors. Fifteen articles were identified that reported 25
different factors associated with OAP non-adherence.
Factors were categorised into: Demographic,
Treatment, Healthcare System Processes, Clinical,
Opportunity (ie, factors outside the patients, such as
cost and healthcare access) and Psychosocial. It was
not possible to determine if any of these factors were
more impactful than others, either overall or
temporally. Review 2: interventions. Six articles were
identified that described interventions targeting
adherence in patients with acute coronary syndromes
(ACS)/coronary artery disease (CAD). Four broad
categories of intervention were identified: treatment
counselling and education, educational materials, SMS
reminders and telephone monitoring and reinforcement
delivered different practitioners. Only reminder-based
interventions had a consistently successful impact on
adherence outcomes at both 3 and 12 months. A
number of factors are associated with OAP non-
adherence, and encouragingly, there is some evidence
of the effectiveness of intervention to modify treatment
adherence in patients with ACS/CAD. Future evaluations
ensuring a better cohesion between the factors studied
as associated with non-adherence and those targeted
by intervention would further increase understanding
and lead to improved results.
INTRODUCTION
Current evidence demonstrates that adher-
ence1 to secondary prevention medication in
acute coronary syndromes (ACS) is subopti-
mal across the globe2 in terms of both per-
sistence3 with treatment and compliance
with dosing instructions throughout the
recommended duration of treatment.
Non-adherence to oral antiplatelet (OAP)
medications is associated with worse out-
comes. Recent studies in patients with coron-
ary artery disease (CAD) suggest a beneﬁt of
extended dual antiplatelet therapy (DAPT)
beyond 1 year, highlighting the importance
of this issue.4
Adherence is a complex health behaviour
with many determining factors,5 which can
vary among individuals and change over time
from uptake to longer term persistence.
Interventions designed to target these factors
have the potential to improve patient out-
comes. An explicit examination of these dif-
ferent factors, how they may change over the
course of treatment and what interventions
have been successful has not been conducted.
Furthermore, while published interven-
tions have been shown to signiﬁcantly
improve adherence in patients with ACS and
those prescribed OAPs, these have varied sig-
niﬁcantly in their design. Even though this
variation is good in terms of the broad evi-
dence base for intervention efﬁcacy, it can
make it difﬁcult to easily identify the optimal
intervention for a particular causal factor
and how this may vary over time.
In the light of this uncertainty, we have
conducted two closely linked systematic
reviews. The ﬁrst review aimed to understand
factors associated with non-adherence to
OAPs in ACS and examine how the impact
of these factors may change over time. The
second review looked at adherence interven-
tions in CAD populations, to determine what
optimal interventions may look like over the
time span of the treatment course. We then
aimed to combine insights from both reviews
in the hope of identifying opportunities for
improving future intervention designs.
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Definition of reviews
Review 1: factors—factors associated with patient non-
adherence to OAPs in ACS and how these vary over the
treatment time frame.
Review 2: interventions—interventions and their behav-
iour change components that have demonstrated posi-
tive outcomes on the identiﬁed factors and adherence
in patients with CAD.
METHODS
The systematic reviews were performed using PRISMA
guidelines.6 This process is described in more detail
below and ﬁgures 1 and 2 show the outcomes of this
process in terms of inclusion and exclusion of papers.
Search strategy
For both reviews, we searched the following compu-
terised databases: CINAHL Plus, MEDLINE, PsycINFO
and PubMed and included studies from 2000 to June
2015. The search terms used were:
Review 1: factors
A: (acute coronary syndrome or ACS or STEMI or ST
segment elevation myocardial infarction or NSTEMI or
non-ST segment elevation myocardial infarction or myo-
cardial infarction or MI or unstable angina or percutan-
eous coronary intervention or PCI or stent* or coronary
artery disease or CAD or ischaemic heart disease or
ischemic heart disease)
AND
B: (persist* or discontinu* or adheren* or complian* or
concord* or nonadheren* or noncomplian* or noncon-
cord*or medication use)
AND
C: (clopidogrel or prasugrel or ticagrelor or thienopyri-
dines or P2Y12 inhibitors or Oral antiplatelets or OAP
or Dual antiplatelet therapy or DAPT)
Review 2: interventions
A and B as per ‘Review 1: Factors’ above plus:
C: (interven* or randomised controlled trial or RCT)
In addition, reference list reviews of identiﬁed relevant
papers were also conducted, and both sets of search
ﬁndings were considered for inclusion in either part of
the review.
Inclusion and exclusion criteria
Review 1: factors
We included papers in which: all participants were pre-
scribed an OAP after an acute coronary event or a separ-
ate analysis of factors correlated with OAP adherence
was available; adherence or discontinuation and at least
one predictor of non-adherence was measured, and the
association between them was statistically examined.
We excluded papers in which: participants were pre-
scribed aspirin only, and in which OAP discontinuation
was physician-initiated.
Review 2: interventions
We included adherence interventions in which: partici-
pants were diagnosed with ACS/CAD; adherence data to
ACS/CAD medication were available, either primarily or
as part of subanalyses.
Quality analysis
Using the following rating tools, two researchers independ-
ently conducted a quality assessment of included papers:
Figure 1 PRISMA process flow
for review 1 Factors. CAD,
coronary artery disease; OAP,
oral antiplatelet therapy.
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Review 1: factors
STrengthening the Reporting of OBservational studies in
epidemiology—STROBE7
Studies were included if they were able to demonstrate
positive outcomes on all of the relevant components of
the checklist.
Review 2: interventions
Jadad scale8
Studies were included if they scored 4 points or more on
the Jadad scale or if appropriate compensations had
been made to mitigate quality factors out of the control
of the researchers.
Discrepancies were resolved by joint review and
consensus.
Data extraction
In addition to data on quality assessment, two individuals
independently extracted data from all identiﬁed studies
based on predeﬁned data extraction strategy.
Data were initially extracted to explore factors impact-
ing adherence overall. Since there were insufﬁcient data
for a separate analysis of the different categories of non-
adherence, the data are presented as a combined set of
ﬁndings for factors impacting adherence overall.
However, the different types of adherence are included
on a study-by-study basis in table 1.
Since the cut-off deﬁnitions of ‘older’ and ‘younger’
age were not consistent across the studies, where age was
cited as a predictive factor, data were further explored to
determine direction and the age cut-off (where this was
not explicitly listed, the mean age of the non-adherent
group was used as the age cut-off criterion).
Data analyses
Meta-analysis was not appropriate for either review
because of the methodological heterogeneity. Thus, a
narrative review process was conducted, whereby results
have been synthesised and similarities and differences
explored and described descriptively.9
RESULTS
Review 1: factors
Overview
Fifteen studies from seven countries met the inclusion cri-
teria.10–24 The majority of studies reviewed adherence to
clopidogrel,10 11 13 15–17 24 one to prasugrel, one to ticagre-
lor and the remaining to either thienopyridines or P2Y12
inhibitors. The studies included a total sample size of
21 954 patients, with a mean sample size of 1464 (range
184–10 465) patients, with a mean of 75% men per study.
An overview of these studies is provided in table 2.
Study methods and settings
Eleven studies were prospective observational
studies;10–17 19 20 22 four were retrospective database
studies.18 21 23 24 A single study was conducted in a
primary care setting,10 with the rest being from second-
ary care or registry/prescription data.
Figure 2 PRISMA process flow
for review 2 Interventions. ACS/
CAD, acute coronary syndromes/
coronary artery disease; OAP,
oral antiplatelet therapy.
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Table 1 Overview of studies exploring factors relating to adherence to OAPs, including study design, significant outcomes
and measurement time points
Study type, collection
methods, sample size
Significant factors impacting
non-adherence
Measurement time
point
(postdischarge;
months)
Author, year,
country 1 3 6 12
Bally, 2012,
Switzerland
Observational self-report
(questionnaire to GPs and
patients)
n=204
Demographic
▸ Older age
Treatment
▸ Side effects (experienced)
X X
Blich, 2012, Israel Observational self-report,
interview with physician,
medical record review
n=314
Demographic
▸ Unemployed
▸ Ethnicity (non-Jew)
▸ Low socioeconomic status
System process
▸ No referral to cardiologist at
discharge
▸ No medication instruction at
discharge
X
Deghani, 2014,
Spain
Prospective, observational
registry data review
n=248
Demographic
▸ Older age
▸ Ethnicity (non-white)
▸ Female gender
Clinical
▸ Prior cardiovascular procedure
Treatment
▸ Side effects (experienced)
X
Ferreira-Gonzalez,
2010, Spain
Prospective self-report
(interviews with patients),
secondary care
n=1622 (182 on clopidogrel)
Demographic
▸ Being an immigrant
Treatment
▸ Concomitant drugs (psychotropic)
X
Gencer, 2015,
Switzerland
Prospective self-report
(interviews with patients),
secondary care
n=3055 (2597 on P2Y12
inhibitor)
Demographic
▸ Older age
Treatment
▸ Side effects (experienced)
Opportunity
▸ Cost
Psychosocial
▸ Low treatment necessity
X
Kubica, 2015,
Poland
Prospective, observational,
prescription database review
n=184
Demographic
▸ Male gender
Clinical
▸ ADP-PA during hospitalisation
▸ STEMI
▸ 3-vessel CAD*
X
Melloni, 2009, USA Prospective self-report
(interviews with patients),
secondary care
n=1077 (816 on clopidogrel)
Demographic
▸ Lower level of education
Clinical
▸ Prior cardiovascular procedure
▸ Comorbidities
▸ Less clinical follow-up
Treatment
▸ Greater number of medicines at
discharge
Opportunity
▸ Cost
Psychosocial
▸ Forgetting
X
Continued
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Table 1 Continued
Study type, collection
methods, sample size
Significant factors impacting
non-adherence
Measurement time
point
(postdischarge;
months)
Author, year,
country 1 3 6 12
Muntner, 2011, USA Prospective self-report
(interview with patient),
secondary care
n=285
Opportunity
▸ Cost
▸ Access/logistics
Psychosocial
▸ Poor relationship with doctor
▸ Low adherence at baseline
X
Nordstrom, 2013,
USA
Retrospective, prescription
database review
n=1340
Clinical
▸ Prior PCI*
▸ Prior depression*
▸ Prior bleeds*
▸ Pre-existing cardiovascular condition
Psychosocial
▸ Low adherence at baseline
Treatment
▸ Baseline statin use*
▸ Baseline anticoagulant use*
X
Pallares, 2009, USA Prospective self-report
(interview with patient),
secondary care
n=257
Clinical
▸ Prior cardiovascular procedure
Treatment
▸ Side effects (experienced)
System process
▸ No information at discharge
Opportunity
▸ Cost
▸ Access/logistics
Psychosocial
▸ Low treatment necessity
▸ Low understanding of treatment
X X
Poh, 2009,
Singapore
Prospective registry database
review
n=207
Demographic
▸ Not living with caregiver
▸ Being single
Clinical
▸ Lower BMI
X
Shimony, 2010,
Israel
Retrospective prescriptions
database
n=1397
Demographic
▸ Low socioeconomic status
X
Spertus, 2006, USA Prospective self-report
(patient interview), secondary
care
n=500
Demographic
▸ Older age
▸ Lower level of education
Clinical
▸ Prior anaemia
▸ Pre-existing cardiovascular condition
System process
▸ No information at discharge
X
Tuppin, 2010,
France
Retrospective prescription
database
n=1056
Demographic
▸ Older age
Treatment
▸ Prior use of clopidogrel*
Clinical
▸ Comorbidities
▸ Stent implantation*
Opportunity
▸ Cost
X
Continued
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Time frames
Only one study10 measured adherence at two different
time points (6 and 12 months), and another19 reported
data at 3 and 6 months, but this was based on the treat-
ment indication and data were not separated out
between time points. Across the studies, three examined
adherence outcomes at 1 month,12 17 22 three at 3
months,11 16 19 three at 6 months,10 19 23 one at 9
months15 and seven at 12 months.10 13 14 18 20 21 24
Adherence measures and analysis
Seven studies used bespoke patient questionnaires or
interviews,10 12–14 16 19 20 one used the Morisky
Medication Adherence Scale (MMAS-8),25 one used a
pill count mechanism,15 ﬁve examined registries or hos-
pital databases,18 21–24 and one used mixed methods,
including a bespoke questionnaire and medical records
data.
Eleven studies examined relationships between factors
and outcomes using logistic regression analyses,11–13
15 16 18 20–24 two performed a correlational analysis,10 19
one performed a stratiﬁed analysis,14 and one looked at
ORs.17 In terms of the type of adherence observed, eight
studies examined persistence only,10–14 16 20 22 four com-
pliance only,15 17 21 23 and three examined both.18 19 24
Factors impacting adherence
Full results are shown in table 2. This summary presents
only factors that were found to be signiﬁcantly corre-
lated with non-adherence in more than a single study.
All factors identiﬁed are negatively related to adherence
unless otherwise stated. Overall, 25 different causal
factors were identiﬁed across the studies and we have
clustered these into the following six groups:
1. Demographic variables
Demographic factors that signiﬁcantly correlated with
non-adherence in more than one study were older age
(>67 years),10 12 14 22 23 lower level of education16 22 and
ethnicity.11 12
2. Treatment variables
The most prevalent treatment reason given for non-
adherence was experience of side effects which signiﬁ-
cantly correlated with non-adherence in all studies in
which it was measured.10 12 14 19 Prior use of clopidogrel
was associated with non-adherence in one study24 and
greater adherence in another.23
3. Healthcare system process variables
A lack of discharge information provided to patients
from the hospital was an identiﬁed factor relating to
non-adherence in three studies.11 19 22
4. Clinical variables
Comorbidities were measured in 11 studies, and 3
studies found a signiﬁcant effect.16 23 24 Pre-existing car-
diovascular disease was also related to non-adherence in
two studies.18 22
5. Opportunity variables (ie, factors outside the
patients, such as cost and healthcare access).
Cost was signiﬁcantly related to non-adherence in ﬁve
studies,14 16 17 19 23 either as directly described by
patients or linked to insurance/copay issues. Two studies
demonstrated the negative impact of logistic/access difﬁ-
culties on adherence.17 19
6. Psychosocial variables
Patient-related factors that demonstrated an impact on
adherence included low treatment necessity beliefs14 19
and a previous history of low adherence.17 18
Owing to the heterogeneous nature of the studies, the
limited number of longitudinal, multiple time point
studies and the broad dispersion across different time
frames, it was not possible to determine any clear pat-
terns of different factors as having an impact on adher-
ence outcomes at different times, even when collapsing
the factors into the cluster groupings as shown above.
Similarly, there there was a broad range of factors
studied, it was not possible to statistically determine the
Table 1 Continued
Study type, collection
methods, sample size
Significant factors impacting
non-adherence
Measurement time
point
(postdischarge;
months)
Author, year,
country 1 3 6 12
Zhu, 2011, USA Retrospective prescription
database
n=10 465
Demographic
▸ Younger age
Clinical
▸ Comorbidities
▸ PCI with no stent
▸ Prior hospitalisation for cardiovascular event
Treatment
▸ Prior use of clopidogrel
X
*Associated with greater adherence.
ADP-PA, ADP-induced platelet aggregation; BMI, body mass index; CAD, coronary artery disease; GP, general practitioner;
PCI, percutaneous coronary intervention; STEMI, ST segment elevation myocardial infarction.
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Table 2 Overview of intervention studies, including factors targeted, time frames for delivery and outcomes
Author, year,
country, sample
size, and
treatment type
Intervention description
(type, setting, delivery)
Factors
targeted
Intervention time point(s) by channel/technique
Significant outcomes
on adherence and
effect sizeChannel Predischarge
0–1
month
1–3
months
3–6
months
6–12
months
Gujral, 2014,
Australia
n=200 (100 per
group)
Lipid-lowering
agents ACE-I/ARB
or β-blocker
▸ Community pharmacy
counselling on
treatment beliefs in
addition to usual care
from the community
pharmacist (monthly
adherence checks
and practical
treatment discussion)
▸ Treatment
knowledge
▸ Treatment
necessity
▸ Treatment
concerns
Face-to-face community
pharmacy adherence
check and practical
treatment discussion
X X X X No statistically
significant outcomes on
adherence as measured
by prescription refill
(MPR≥80%), or
self-reported MARS at 6
and 12 months
Face-to-face community
pharmacy counselling
based on individual
treatment beliefs
uncovered by researchers
X X
Researcher interviews
with patients to uncover
individual treatment
X X X
Khonsari, 2015,
Malaysia
n=62 (31 per
group)
Cardiac
medications ‘in
general’
▸ Automated text
message reminders
for 8 weeks in addition
to usual care (cardiac
rehabilitation and 6–
8-week follow-up with
cardiologist)
▸ Forgetting Daily SMS reminders X X At 8 weeks
postdischarge, 65% of
participants in the
intervention group had
high self-reported
adherence (MMAS-8=8)
compared with 13% in
the usual-care group
(p<0.001)
Prescription refill SMS
reminders
X
Fortnightly telephone
calls from research team
to check receipt of SMS,
check for emergency
admissions and
appointment attendance
X X
Muñiz, 2010,
Spain
n=1757 (867
intervention 890
control)
Aspirin
Clopidogrel
β-blockers
ACE-inhibitors
ARA II Statins
▸ Physician-led
interviews with
supporting
educational materials
in addition to usual
discharge information
▸ Patient and
healthcare
professional
relationship
▸ Treatment
knowledge
▸ Treatment
necessity
▸ Treatment
concerns
▸ Illness
coherence
30-to-40 min hospital
physician interview with
patient and next of kin
X X No statistically
significant outcomes on
adherence as measured
by self-reported
persistence with
treatment at 6 months.
Signed agreement
between physician and
patient on therapeutic
aims
X
Written educational
materials (treatment,
illness, secondary
prevention)
X X
Inbound telephone
support
X X X
Palacio, 2015,
USA
n=422 (213
intervention 209
control)
▸ Phone-based
motivational
interviewing (MINT) vs
educational video
▸ Self-efficacy
▸ Treatment
knowledge
▸ Treatment
necessity
60 min quarterly
motivational
interviewing-based call
conducted by nurse with
patient
X X X X At 12 months
postprocedure, 64% of
patients in the MINT
group had high
adherence (MPR≥80)
Continued
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Table 2 Continued
Author, year,
country, sample
size, and
treatment type
Intervention description
(type, setting, delivery)
Factors
targeted
Intervention time point(s) by channel/technique
Significant outcomes
on adherence and
effect sizeChannel Predischarge
0–1
month
1–3
months
3–6
months
6–12
months
Antiplatelet
therapy
▸ Treatment
concerns
▸ Illness control
▸ Illness
coherence
compared with 50% in
video group (p≤0.001)
Mean MPR in MINT
group was 0.77
compared with 0.70 in
video group (p≤0.005)
Treatment education
video
X
Rinfret, 2013,
Canada
n=300 (150 per
group)
Clopidogrel
▸ Nurse telephone
adherence follow-up
in addition to usual
care
▸ Treatment
knowledge
▸ Treatment
necessity
▸ Illness
coherence
5–10 min nurse calls to
the patient to check
adherence and reinforce
need for treatment
X X X X 12-month persistence
was 87.2% in the
intervention group
compared with 43.1% in
the usual care group
(p=<0.001) as
measured by pharmacy
prescription refill data.
12-month median
adherence (number of
pills/365 days) was
99.3% in the
intervention group
compared with 91.5% in
the usual care group
(p≤0.001) as measured
by pharmacy
prescription refill data.
Uysal, 2015,
Turkey
n=200 (100 per
group)
Aspirin Plavix ACE
inhibitors
β-blockers
Calcium channel
blockers Diuretics
Statins
▸ Individual education
and counselling and
supporting
educational materials
in addition to usual
care
▸ Treatment
knowledge
▸ Illness
coherence
▸ Emotional
well-being
60 min face-to-face
education and
counselling session
X At 3 months
postdischarge,
intervention group had
higher mean adherence
(MMAS=1.4) compared
with control group
(MMAS=3.6) (p≤0.005).
5–10 min telephone
education and
counselling session
X X
MARS, Medication Adherence Report Scale; MMAS, Morisky Medication Adherence Scale; MPR, medication possession ration.
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relative predictive strength of the factors, as those that
were studied multiple times showed different results.
Figure 3 shows the frequency of signiﬁcant and non-
signiﬁcant ﬁndings for any factors that were investigated
in four studies or more.
Review 2: interventions
Overview
Six studies met the inclusion criteria,26–31 four were
focused on patients with ACS26–28 31 and two were
focused on patients with stable CAD.29 30 All were single-
country studies from Australia,26 Canada,30 Malaysia,27
Spain,28 Turkey31 and the USA.29 The studies included a
total sample size of 2831 patients, with a mean sample
size of 472 (range 62–1757) patients and a mean of 75%
men per study. An overview of these studies is provided
in table 3.
Intervention design
Intervention type and delivery
The majority of interventions were based on treatment
education and counselling,26 28 29 31 with one being
delivered by community pharmacists,26 one by physi-
cians,28 one by nurses29 and one by the study research-
ers themselves.31 Only one of the education and
counselling studies referred to a speciﬁc intervention
methodology, namely motivational interviewing.29 Three
studies included a mix of face-to-face and telephone
support, with telephone support being offered after
initial face-to-face counselling, either outbound31 or
inbound,28 and one study including telephone calls
from researchers to elicit treatment beliefs, which were
then shared with community pharmacists delivering the
intervention.26 When time frames were presented, initial
counselling sessions lasted from 30 to 60 min,28 29 31
with shorter follow-up sessions described as being 5–
10 min long.31 Other interventions included treatment
and prescription SMS reminders with monitoring calls
from the research team,27 a signed contract between the
patient and physician on treatment aims,28 and educa-
tional materials, both written and video.28 29 A single
study consisted of telephone calls from nurses who
checked adherence and reinforced the importance of
treatment; these calls lasted an average of 5–10 min.30
Only one study was multicomponent.28
Behaviour change techniques
A behaviour change technique (BCT) is deﬁned as ‘an
active component of an intervention designed to change
behaviour’. Technique characteristics include that it be
observable, replicable and an irreducible and active
component of the intervention.32 The BCT taxonomy
(BCTT) was designed to provide a standardised lan-
guage for describing these components.33 None of the
studies explicitly referenced the taxonomy when describ-
ing their intervention design, but in order to review the
interventions in a standardised way, we labelled the
intervention components with their relevant BCT
description as gathered from the study descriptions.
Five BCTs were common across ﬁve of the interven-
tions: instruction on how to perform a behaviour, pro-
viding information about health consequences, salience
of consequences, social support and credible
source.26 28–31 Goal setting, action planning and review
activities were a feature of four interventions,26 28–30 and
three interventions provided explicit feedback on behav-
iour.26 28 29 The motivational interviewing intervention
by Palacio et al29 featured a number of unique techni-
ques compared with the other interventions. These were
anticipated regret, pros and cons, comparative imagin-
ing of future outcomes, verbal persuasion of capability
and social comparison. Other singularly occurring, expli-
cit techniques were prompts/cues and monitoring of
behaviours by others without feedback,27 behavioural
contract28 and reduction of negative emotions.31
Time frames
Three study interventions lasted for 12 months, with
interventional calls or face-to-face counselling occurring
approximately once per quarter.26 29 30 Three studies
included counselling or information at discharge from
hospital.26 28 31 The SMS intervention lasted for 8 weeks
and was the only intervention that featured daily contact
(via SMS) and fortnightly telephone calls to check
receipt of messaging and outcomes. This intervention
also included a single prescription reminder at
30 days.27 The remaining two interventions lasted
3 months, with one including a single follow-up post-
discharge intervention28 and one with two follow-ups fol-
lowing discharge intervention.31
Adherence measures
Four studies used self-report measures, with two using
the MMAS25 with a cut-off point of eight to deﬁne
adherence, and one using the Medication Adherence
Rating Scale (MARS)32 (cut-off not described or
reported) and one collecting self-reported persistence
data at 6 months.28 Three studies used prescription reﬁll
data to determine medication possession ratio (MPR)
with ≥80% being considered adherent.26 29 30
Figure 3 Relative impact of adherence-related factors that
were measured in at least four studies. CABG, coronary artery
bypass grafting; MI, myocardial infraction; PCI, percutaneous
coronary intervention.
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Adherence outcomes
Four of the six interventions demonstrated a signiﬁcant
impact on adherence. The 8-week SMS reminder interven-
tion by Khonsari et al27 demonstrated 52% more patients
self-reporting high adherence as measured by MMAS at
the end of the intervention (p=<0.001). The 12-month
nurse-delivered motivational interviewing intervention
demonstrated 14% more patients with a high MPR
(≥80%) at the end of the study (p=<0.001) and a higher
mean medication intake across the 12 months (0.77
compared with 0.70 (p=<0.005)).29 The 12-month nurse
adherence follow-up by Rinfret et al30 demonstrated a
42.1% higher number of persistent patients in the inter-
vention group (p=<0.001) and a 7.8% higher median
adherence rate (p=<0.001). The 3-month education and
counselling intervention by Uysal and Ozcan,31 deliv-
ered by a research team, demonstrated higher levels of
self-reported mean adherence as measured by MMAS
(p=<0.005).
Integrated findings
This section attempts to integrate the ﬁndings from the
two reviews and describes which identiﬁed OAP non-
adherence factors were targeted by the interventions
identiﬁed in the second review, and whether these were
successful.
The interventions have attempted to target a number
of determinants of treatment non-adherence using a
range of approaches, and table 3 provides an overview of
the ﬁndings. The determinants that have been targeted
can be broadly divided into treatment and psychosocial
factors, and the interventions varied in their efﬁcacy in
achieving improved adherence outcomes.
In attempting to improve information provision, the
use of treatment and illness counselling26 did not result
in improved adherence, whereas the use of written edu-
cational materials was successful in one study31 but not
another.28 However, a 12-month nurse-led motivational
interviewing intervention that targeted information pro-
vision and other factors, including treatment side
effects,29 did produce signiﬁcant improvements.
Three different types of psychosocial factors were tar-
geted by a number of different interventional
approaches with mixed success. The use of treatment
and illness counselling over 3 months to improve the
patient/physician relationship and patients’ necessity
beliefs was successful.31 Two of the other interventions
that targeted necessity beliefs by using motivational
interviewing29 and nurse telephone follow-up30 showed
improved adherence outcomes, whereas the use of a
signed agreement between the doctor and patient28 did
not.
Finally, patient forgetting was a target for two success-
ful interventions, one using SMS reminders27 and the
other using a nurse-led telephone follow-up.30
DISCUSSION
These two linked systematic reviews sought to under-
stand (1) the most prevalent factors impacting adher-
ence to OAPs over the course of treatment and (2)
which interventions successfully modiﬁed these factors,
Table 3 Factors that were both identified as having an impact on adherence and addressed by intervention
Identified adherence factors
that were targeted in the intervention Intervention used
Modified by intervention
(Study)
Treatment factors
No information at discharge from hospital
(low treatment knowledge)
Treatment and illness counselling
(face-to-face and telephone)
No (Gujral et al,26 2014)
Written educational materials No (Muñiz et al,28 2010)
Yes (Uysal and Ozcan,31 2015)
Nurse-led motivational interviewing Yes (Palacio et al,29 2015)
Medication side effects
(treatment concerns)
Treatment and illness counselling
(face-to-face and telephone)
No (Muñiz et al,28 2010)
Nurse-led motivational interviewing Yes (Palacio et al,29 2015)
Psychosocial factors
Patient and physician relationship Treatment and illness counselling
(face-to-face and telephone)
Yes (Uysal and Ozcan,31 2015)
Treatment necessity Treatment and illness counselling
(face-to-face and telephone)
Yes (Uysal and Ozcan,31 2015)
Signed agreement between physician and
patient
No (Muñiz, et al,28 2010)
Nurse-led motivational interviewing
(telephone)
Yes (Palacio et al,29 2015)
Nurse-led telephone follow-up Yes (Rinfret et al,30 2013)
Forgetting SMS reminders (daily treatment and
30-day prescription refill)
Yes (Khonsari et al,27 2015)
Nurse-led telephone follow-up Yes (Rinfret et al,30 2013)
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to help guide clinicians in practice to address adherence
risk factors.
Factors impacting adherence to OAPs in patients with ACS
In this review, we found the number of studies addres-
sing this issue to be limited and the evidence somewhat
conﬂicting. In total, there were 25 different factors
found to be correlated with adherence to OAPs. The
factors studied seemed to be skewed to clinical and
demographic variables most likely because they are
easiest to capture. In general, factors that were found to
be signiﬁcant are well known. Patients at risk of being
non-adherent included those with a higher number of
comorbidities, lower education, with low treatment
necessity beliefs and previous experience of side effects
and those who forget. Lack of discharge information,
difﬁculties in accessing healthcare facilities and not
being followed up by a cardiologist all had a negative
impact on adherence. Notably, depression, which is a
frequent ACS comorbidity that is consistently linked with
lower treatment adherence, was not investigated in any
of the studies34 aside from Nordstrom et al who assessed
prior depression only. Methodological heterogeneity in
the studies made it difﬁcult to determine if any of these
factors were more impactful than others and also when
during the course of the treatment they were most
signiﬁcant.
Interventions to address non-adherence in patients with
ACS/CAD
There were four broad categories of intervention found
as part of this review: treatment counselling and educa-
tion (telephone and face-to-face), educational materials,
SMS reminders and telephone monitoring and
reinforcement delivered by a range of practitioners.
Reminder-based interventions were consistent in their
success,27 30 demonstrating positive outcomes on persist-
ence and compliance both at 3 and 12 months.
Most of the interventions incorporated education-
based BCTs, such as information provision and behav-
ioural instruction,26 28–31 which is an important founda-
tion to enable behaviour change.35 Only one
intervention did not feature an educational component;
this was the one by Khonsari et al,27 which used
prompts/cues and monitoring (without feedback) to
improve adherence behaviours. The other successful
interventions provided a differing range of techniques
in addition to education, with goal setting, action plan-
ning and feedback/review featuring in multiple
studies,26 28–30 which have been shown to be important
in helping to turn intention into action.36 37
Social-based techniques, such as the provision of support
and providing information from a credible source,
were also featured as supplementary techniques to edu-
cation, although it is not possible to determine whether
this was planned or simply a natural feature of who was
delivering the intervention.26 28–31 The motivational
interviewing-based intervention provided the broadest
range of BCTs, as it is built on core principles of com-
munication and behaviour change.27 It is encouraging
to note that a range of behaviour change techniques
have been shown to improve adherence, but further
work is clearly needed to conﬁrm which are most effect-
ive for targeting the different factors causing non-
adherence, which were identiﬁed in the ﬁrst review.
None of the interventions reported screening for indi-
vidual risk factors prior to starting the study. While the
nature of the counselling-based studies, particularly the
motivational interviewing intervention, lends itself to
addressing individual needs, these interventions were
applied to all in the same frequency, regardless of differ-
ing baseline characteristics, which may have helped
determine more concretely the unmet needs of these
patients. Moreover, the lack of consistent time frames or
comparison between time points meant that it was not
possible to draw conclusions around the most appropri-
ate time to intervene.
The impact of interventions on factors identified as
impacting adherence to OAPs in patients with ACS
The interventions in this review mainly focused on tar-
geting psychosocial and treatment (medication)-related
factors, although these were studied less frequently in
the research from the ﬁrst review. Factors such as illness
and treatment perceptions are more modiﬁable and,
therefore, better suited to intervention compared with
factors such as age and ethnicity.34 Thus, what this
review does demonstrate is an apparent disconnect
between research into factors impacting adherence and
the focus of adherence interventions. The body of
research exploring factors impacting adherence was
heavily weighted towards examining demographic and
clinical variables, rather than trying to understand the
more modiﬁable factors or to examine how demo-
graphic and clinical features are modifying outcomes.
IMPLICATIONS FOR CLINICAL PRACTICE
The present ﬁndings suggest that patients at risk for
non-adherence can be identiﬁed in hospital and include
those suffering from several comorbidities, those taking
several medications and those with less education and
fewer economic resources. Given the limited resources
of most healthcare systems, the ﬁndings from this review
suggest that medical adherence can be improved by
early identiﬁcation of the at-risk patient in need of a
more intense follow-up, expansion of nurse-led pro-
grammes, particularly those that incorporate informa-
tion provision, SMS reminders, goal setting, monitoring
and support.
LIMITATIONS AND FUTURE RESEARCH
These ﬁndings are limited due to the heterogeneous
nature of the studies in both reviews. It was not possible
to determine the temporal effects of different adher-
ence factors and intervention due to the limited
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number of longitudinal studies. None of the studies
explicitly referred to BCTs, and so the intervention
content provided may not be comprehensive.
Since there is declining adherence to OAPs over the
course of treatment, there is a need for longitudinal
studies to provide a better understanding of how delivery
of interventions can best be timed. Similarly, more multi-
arm studies are needed to explore the impact of different
intervention components at different times, particularly
for those who are at higher risk of non-adherence.
Finally, there is certainly scope for interventions targeting
depression and its known effects on adherence.
SUMMARY
These reviews suggest that there is a broad range of
potential factors to consider in relation to adherence to
OAPs, and that there is an opportunity to positively
impact some of these factors, in particular those classi-
ﬁed as treatment related and psychosocial, to improve
adherence to OAPs.
The successful interventions incorporate a number of
core BCTs, particularly information provision, remin-
ders, goal setting, monitoring and feedback, and
support. However, the apparent disparity between
factors studied and those targeted suggests that there is
opportunity for better cohesion between exploratory
and interventional studies in this area. Similarly, a lack
of longitudinal studies has limited our ability to under-
stand any temporal effects that may be occurring in
terms of adherence factors and the potential focus of
interventions over the full treatment course.
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15. Kubica A, Obońska K, Kasprzak M, et al. Prediction of high risk
of non-adherence to antiplatelet treatment. Kardiol Pol
2016;74:61–7.
16. Melloni C, Alexander KP, Ou FS, et al. Predictors of early
discontinuation of evidence-based medicine after acute coronary
syndrome. Am J Cardiol 2009;104:175–81.
17. Muntner P, Mann DM, Woodward M, et al. Predictors of low
clopidogrel adherence following percutaneous coronary intervention.
Am J Cardiol 2011;108:822–7.
18. Nordstrom BL, Simeone JC, Zhao Z, et al. Adherence and
persistence with prasugrel following acute coronary syndrome with
percutaneous coronary intervention. Am J Cardiovasc Drugs
2013;13:263–71.
19. Pallares MJ, Powers ER, Zwerner PL, et al. Barriers to clopidogrel
adherence following placement of drug-eluting stents. Ann
Pharmacother 2009;43:259–67.
20. Poh CL, Chan MY, Lau C, et al. Prevalence and predictors of
premature discontinuation of dual antiplatelet therapy after
drug-eluting stent implantation: importance of social factors in Asian
patients. Intern Med J 2011;41:623–9.
21. Shimony A, Zahger D, Ilia R, et al. Impact of the community’s
socioeconomic status on characteristics and outcomes of patients
undergoing percutaneous coronary intervention. Int J Cardiol
2010;144:379–82.
22. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors,
and outcomes of premature discontinuation of thienopyridine therapy
after drug-eluting stent placement results from the PREMIER
registry. Circulation 2006;113:2803–9.
23. Tuppin P, Neumann A, Danchin N, et al. Evidence-based
pharmacotherapy after myocardial infarction in France:
adherence-associated factors and relationship with 30-month
mortality and rehospitalization. Arch Cardiovasc Dis
2010;103:363–75.
24. Zhu B, Zhao Z, Mccollam P, et al. Factors associated with
clopidogrel use, adherence, and persistence in patients with acute
coronary syndromes undergoing percutaneous coronary intervention.
Curr Med Res Opin 2011;27:633–41.
25. Horne R, Weinman J, Hankins M. The beliefs about medicines
questionnaire: the development and evaluation of a new method for
assessing the cognitive representation of medication. Psychol Health
1999;14:1–24.
26. Gujral G, Winckel K, Nissen LM, et al. Impact of community
pharmacist intervention discussing patients’ beliefs to improve
medication adherence. Int J Clin Pharm 2014;36:1048–58.
27. Khonsari S, Subramanian P, Chinna K, et al. Effect of a reminder
system using an automated short message service on medication
adherence following acute coronary syndrome. Eur J Cardiovasc
Nurs 2015;14:170–9.
28. Muñiz J, Gómez-Doblas JJ, Santiago-Pérez MI, et al., CAM2 Project
working group. The effect of post-discharge educational intervention
on patients in achieving objectives in modifiable risk factors six
12 Johnston N, Weinman J, Ashworth L, et al. Open Heart 2016;3:e000479. doi:10.1136/openhrt-2016-000479
Open Heart
group.bmj.com on November 25, 2016 - Published by http://openheart.bmj.com/Downloaded from 
months after discharge following an episode of acute coronary
syndrome, (CAM-2 Project): a randomized controlled trial. Health
Qual Life Outcomes 2010;8:137.
29. Palacio AM, Uribe C, Hazel-Fernandez L, et al. Can phone-based
motivational interviewing improve medication adherence to
antiplatelet medications after a coronary stent among racial
minorities? A randomized trial. J Gen Intern Med 2015;30:469–75.
30. Rinfret S, Rodés-Cabau J, Bagur R, et al., EASY-IMPACT
Investigators. Telephone contact to improve adherence to dual
antiplatelet therapy after drug-eluting stent implantation. Heart
2013;99:562–9.
31. Uysal H, Ozcan S¸. The effect of individual education on patients’
physical activity capacity after myocardial infarction. Int J Nurs Pract
2015;21:18–28.
32. Morisky DE, Green LW, Levine DM. Concurrent and predictive
validity of a self-reported measure of medication adherence. Med
Care 1986;24:67–74.
33. Michie S, van Stralen MM, West R. The behaviour change wheel: a
new method for characterising and designing behaviour change
interventions. Implement Sci 2011;6:1–11.
34. Moss-Morris R, Weinman J, Petrie K, et al. The revised illness
perception questionnaire (IPQ-R). Psychol Health 2002;17:1–16.
35. Whitehead D, Russell G. How effective are health education
programmes—resistance, reactance, rationality and risk?
Recommendations for effective practice. Int J Nurs Stud
2004;41:163–72.
36. Sniehotta FF, Scholz U, Schwarzer R. Bridging the intention–
behaviour gap: planning, self-efficacy, and action control in the
adoption and maintenance of physical exercise. Psychol Health
2005;20:143–60.
37. Goodwin L, Ostuzzi G, Khan N, et al. Can we identify the active
ingredients of behaviour change interventions for coronary heart
disease patients? A systematic review and meta-analysis. PLoS
ONE 2016;11:e0153271.
Johnston N, Weinman J, Ashworth L, et al. Open Heart 2016;3:e000479. doi:10.1136/openhrt-2016-000479 13
Coronary artery disease
group.bmj.com on November 25, 2016 - Published by http://openheart.bmj.com/Downloaded from 
intervention
coronary syndromes and response to
non-adherence to P2Y12 inhibitors in acute 
Systematic reviews: causes of
Khoury and Clare Moloney
Nina Johnston, John Weinman, Lucy Ashworth, Peter Smethurst, Jad El
doi: 10.1136/openhrt-2016-000479
2016 3: Open Heart 
 http://openheart.bmj.com/content/3/2/e000479
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://openheart.bmj.com/content/3/2/e000479
This article cites 35 articles, 5 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on November 25, 2016 - Published by http://openheart.bmj.com/Downloaded from 
